Pre-treatment of Allogeneic Bone Marrow Recipients with the CXCR4 Antagonist AMD3100 Transiently Enhances Hematopoietic Chimerism without Promoting Donor-specific Skin Allograft Tolerance.

Li Z, Xu X, Weiss ID, Jacobson O, Murphy PM. Pre-treatment of Allogeneic Bone Marrow Recipients with the CXCR4 Antagonist AMD3100 Transiently Enhances Hematopoietic Chimerism without Promoting Donor-specific Skin Allograft Tolerance. Transpl Immunol. 2015.